Koninklijke Philips NV vs BlackRock TCP Capital Corp — how do they compare? Koninklijke Philips NV trades at $24.32 (market cap $23.52B), while BlackRock TCP Capital Corp trades at $4.04 (market cap $337.71M). The key difference: Koninklijke Philips NV is far larger — about 69.6× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (18.88%). Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and BlackRock TCP Capital Corp for 88 Days on average.
| PHG | TCPC | |
|---|---|---|
Market Cap | $23.52B | $337.71M |
Volume | 1,635,069 | 436,109 |
Sector | Health | Financials |
52-Week High | $32.91 | $6.20 |
52-Week Low | $23.81 | $3.13 |
Typical Hold Time | 84 Days | 88 Days |
Enterprise Value | $29.87B | $1.09B |
Dividend Yield | 4.17% | 18.88% |
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
TCPC trades at $3.94, down 1.25% today, with a bearish technical signal and mixed fundamentals. The company reported negative revenue and net income for 2025, though recent earnings beat expectations. A strategic portfolio sale of $523 million aims to reduce leverage, while analyst sentiment leans cautious with 69% hold ratings. The stock shows a low P/B ratio of 0.61, suggesting potential undervaluation relative to assets.
Outlook remains challenged by persistent negative profitability and revenue trends, with projected declines through 2026. The strategic review and dividend yield near 4.3% offer some upside, but risks include class action lawsuits and execution uncertainty. Investors should weigh the discount to book value against fundamental headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →